182 related articles for article (PubMed ID: 19359525)
1. The dietary polyphenols trans-resveratrol and curcumin selectively bind human CB1 cannabinoid receptors with nanomolar affinities and function as antagonists/inverse agonists.
Seely KA; Levi MS; Prather PL
J Pharmacol Exp Ther; 2009 Jul; 330(1):31-9. PubMed ID: 19359525
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs.
Franks LN; Ford BM; Madadi NR; Penthala NR; Crooks PA; Prather PL
Eur J Pharmacol; 2014 Aug; 737():140-8. PubMed ID: 24858620
[TBL] [Abstract][Full Text] [Related]
3. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
[TBL] [Abstract][Full Text] [Related]
4. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen.
Prather PL; FrancisDevaraj F; Dates CR; Greer AK; Bratton SM; Ford BM; Franks LN; Radominska-Pandya A
Biochem Biophys Res Commun; 2013 Nov; 441(2):339-43. PubMed ID: 24148245
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands.
Cascio MG; Bisogno T; Palazzo E; Thomas A; van der Stelt M; Brizzi A; de Novellis V; Marabese I; Ross R; van de Doelen T; Brizzi V; Pertwee R; Maione S; Di Marzo V
Br J Pharmacol; 2006 Oct; 149(4):431-40. PubMed ID: 16953186
[TBL] [Abstract][Full Text] [Related]
6. Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gα
Porcu A; Melis M; Turecek R; Ullrich C; Mocci I; Bettler B; Gessa GL; Castelli MP
Neuropharmacology; 2018 May; 133():107-120. PubMed ID: 29407764
[TBL] [Abstract][Full Text] [Related]
7. The tamoxifen derivative ridaifen-B is a high affinity selective CB
Franks LN; Ford BM; Fujiwara T; Zhao H; Prather PL
Toxicol Appl Pharmacol; 2018 Aug; 353():31-42. PubMed ID: 29906493
[TBL] [Abstract][Full Text] [Related]
8. CB1 cannabinoid receptor-mediated increases in cyclic AMP accumulation are correlated with reduced Gi/o function.
Eldeeb K; Leone-Kabler S; Howlett AC
J Basic Clin Physiol Pharmacol; 2016 May; 27(3):311-22. PubMed ID: 27089415
[TBL] [Abstract][Full Text] [Related]
9. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E
Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development.
Ford BM; Franks LN; Radominska-Pandya A; Prather PL
PLoS One; 2016; 11(12):e0167240. PubMed ID: 27936172
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the pharmacology of imidazolidinedione derivatives at cannabinoid CB1 and CB2 receptors.
Govaerts SJ; Muccioli GG; Hermans E; Lambert DM
Eur J Pharmacol; 2004 Jul; 495(1):43-53. PubMed ID: 15219819
[TBL] [Abstract][Full Text] [Related]
12. An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors.
Savinainen JR; Saario SM; Niemi R; Järvinen T; Laitinen JT
Br J Pharmacol; 2003 Dec; 140(8):1451-9. PubMed ID: 14623770
[TBL] [Abstract][Full Text] [Related]
13. CB1 receptor-independent actions of SR141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells.
Cinar R; Szücs M
J Pharmacol Exp Ther; 2009 Aug; 330(2):567-74. PubMed ID: 19448142
[TBL] [Abstract][Full Text] [Related]
14. Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors.
MacLennan SJ; Reynen PH; Kwan J; Bonhaus DW
Br J Pharmacol; 1998 Jun; 124(4):619-22. PubMed ID: 9690851
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.
Muccioli GG; Wouters J; Charlier C; Scriba GK; Pizza T; Di Pace P; De Martino P; Poppitz W; Poupaert JH; Lambert DM
J Med Chem; 2006 Feb; 49(3):872-82. PubMed ID: 16451053
[TBL] [Abstract][Full Text] [Related]
16. Characterization of structurally novel G protein biased CB
Ford BM; Franks LN; Tai S; Fantegrossi WE; Stahl EL; Berquist MD; Cabanlong CV; Wilson CD; Penthala NR; Crooks PA; Prather PL
Pharmacol Res; 2017 Nov; 125(Pt B):161-177. PubMed ID: 28838808
[TBL] [Abstract][Full Text] [Related]
17. Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity.
Zádor F; Kocsis D; Borsodi A; Benyhe S
Neurochem Int; 2014 Feb; 67():14-22. PubMed ID: 24508403
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel phytocannabinoids from Ganoderma by label-free dynamic mass redistribution assay.
Zhou H; Peng X; Hou T; Zhao N; Qiu M; Zhang X; Liang X
J Ethnopharmacol; 2020 Jan; 246():112218. PubMed ID: 31494202
[TBL] [Abstract][Full Text] [Related]
19. SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.
Rinaldi-Carmona M; Barth F; Congy C; Martinez S; Oustric D; Pério A; Poncelet M; Maruani J; Arnone M; Finance O; Soubrié P; Le Fur G
J Pharmacol Exp Ther; 2004 Sep; 310(3):905-14. PubMed ID: 15131245
[TBL] [Abstract][Full Text] [Related]
20. Characterization of active and inactive states of CB1 receptor and the differential binding state modulation by cannabinoid agonists, antagonists and inverse agonists.
Gullapalli S; Amrutkar D; Gupta S; Kandadi MR; Kumar H; Gandhi M; Karande V; Narayanan S
Neuropharmacology; 2010 Jun; 58(8):1215-9. PubMed ID: 20214912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
